Related Experiment Video
Updated: Mar 31, 2026
06:53
A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA
Published on: December 26, 2015
13.2K
MiniAp-4: A Venom-Inspired Peptidomimetic for Brain Delivery
Benjamí Oller-Salvia1, Macarena Sánchez-Navarro1, Sonia Ciudad1
1Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac, 10, 08028 Barcelona (Spain).
Angewandte Chemie (International Ed. in English)
|October 24, 2015
Summary
Researchers developed MiniAp-4, a cyclic peptide from bee venom, to overcome blood-brain barrier (BBB) delivery challenges. This protease-resistant molecule effectively transports cargo across the BBB into the brain.
Area of Science:
- Neuroscience
- Drug Delivery
- Biochemistry
Background:
- Drug delivery to the central nervous system is hindered by the blood-brain barrier (BBB).
- Existing BBB shuttle peptides face limitations due to protease lability.
- Novel strategies are needed to enhance non-invasive brain drug transport.
Purpose of the Study:
- To develop protease-resistant cyclic peptides for improved blood-brain barrier (BBB) penetration.
- To create an affordable and effective method for delivering therapeutics across the BBB.
- To modify apamin, a bee venom neurotoxin, for enhanced brain targeting and transport.
Main Methods:
- Design and synthesis of cyclic peptide analogues derived from apamin.
- Evaluation of peptide permeability and stability in a human-cell-based BBB model.
- Assessment of cargo translocation (proteins, nanoparticles) using the developed peptides.
- In vivo testing of the most promising peptide in a mouse model for brain delivery.
Main Results:
- A monocyclic lactam-bridged peptidomimetic, MiniAp-4, demonstrated superior permeability.
- MiniAp-4 successfully translocated proteins and nanoparticles across a human BBB model.
- The peptide efficiently delivered cargo across the BBB into the mouse brain parenchyma.
Conclusions:
- Cyclic peptides from venoms offer a promising, protease-resistant approach for BBB drug delivery.
- MiniAp-4 is a potent tool for non-invasively delivering therapeutic cargo across the blood-brain barrier.
- This strategy overcomes limitations of current BBB shuttle peptides, enabling CNS therapies.
Related Concept Videos
01:29Drug Delivery: Parenteral Route
2.4K
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
2.4K
01:24Modified-Release Drug Delivery Systems: Site-Targeted
109
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
109